Stock Analysis on Net

Illumina Inc. (NASDAQ:ILMN)

This company was transferred to the archive: financial data is no longer updated!

Analysis of Long-term (Investment) Activity Ratios

Microsoft Excel LibreOffice Calc

Long-term Activity Ratios (Summary)

Illumina Inc., long-term (investment) activity ratios

Microsoft Excel LibreOffice Calc
Dec 31, 2020 Dec 29, 2019 Dec 30, 2018 Dec 31, 2017 Dec 31, 2016
Net fixed asset turnover 3.51 3.99 3.10 2.96 3.36
Net fixed asset turnover (including operating lease, right-of-use asset) 2.23 2.45 3.10 2.96 3.36
Total asset turnover 0.43 0.48 0.48 0.52 0.56
Equity turnover 0.69 0.77 0.89 1.00 1.09

Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).

Long-term activity ratio Description The company
Net fixed asset turnover An activity ratio calculated as total revenue divided by net fixed assets. Illumina Inc. net fixed asset turnover ratio improved from 2018 to 2019 but then slightly deteriorated from 2019 to 2020 not reaching 2018 level.
Net fixed asset turnover (including operating lease, right-of-use asset) An activity ratio calculated as total revenue divided by net fixed assets (including operating lease, right-of-use asset). Illumina Inc. net fixed asset turnover ratio (with operating lease, right-of-use asset) deteriorated from 2018 to 2019 and from 2019 to 2020.
Total asset turnover An activity ratio calculated as total revenue divided by total assets. Illumina Inc. total asset turnover ratio improved from 2018 to 2019 but then deteriorated significantly from 2019 to 2020.
Equity turnover An activity ratio calculated as total revenue divided by shareholders’ equity. Illumina Inc. equity turnover ratio deteriorated from 2018 to 2019 and from 2019 to 2020.

Net Fixed Asset Turnover

Illumina Inc., net fixed asset turnover calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2020 Dec 29, 2019 Dec 30, 2018 Dec 31, 2017 Dec 31, 2016
Selected Financial Data (US$ in millions)
Revenue 3,239  3,543  3,333  2,752  2,398 
Property and equipment, net 922  889  1,075  931  713 
Long-term Activity Ratio
Net fixed asset turnover1 3.51 3.99 3.10 2.96 3.36
Benchmarks
Net Fixed Asset Turnover, Competitors2
AbbVie Inc. 8.73 11.23 11.36 10.07 9.85
Amgen Inc. 4.96 4.51 4.54 4.37 4.41
Eli Lilly & Co. 2.83 2.83 2.75 2.59 2.57
Gilead Sciences Inc. 4.90 4.91 5.41 7.79 10.45
Johnson & Johnson 4.40 4.65 4.79 4.50 4.52
Merck & Co. Inc. 2.67 3.11 3.18 3.23 3.31
Moderna Inc. 0.67 0.00 0.00
Pfizer Inc. 3.01 3.71 4.01 3.79 3.97
Regeneron Pharmaceuticals Inc. 2.64 2.72 2.61 2.49 2.33
Thermo Fisher Scientific Inc. 5.45 5.38 5.85 5.17 7.09
Zoetis Inc. 3.03 3.23 3.51 3.70 3.54
Net Fixed Asset Turnover, Sector
Pharmaceuticals, Biotechnology & Life Sciences 3.94 4.17 4.32 4.22 4.41
Net Fixed Asset Turnover, Industry
Health Care 7.14 7.21 7.01 6.96 7.16

Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).

1 2020 Calculation
Net fixed asset turnover = Revenue ÷ Property and equipment, net
= 3,239 ÷ 922 = 3.51

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Net fixed asset turnover An activity ratio calculated as total revenue divided by net fixed assets. Illumina Inc. net fixed asset turnover ratio improved from 2018 to 2019 but then slightly deteriorated from 2019 to 2020 not reaching 2018 level.

Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset)

Illumina Inc., net fixed asset turnover (including operating lease, right-of-use asset) calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2020 Dec 29, 2019 Dec 30, 2018 Dec 31, 2017 Dec 31, 2016
Selected Financial Data (US$ in millions)
Revenue 3,239  3,543  3,333  2,752  2,398 
 
Property and equipment, net 922  889  1,075  931  713 
Operating lease right-of-use assets 532  555  —  —  — 
Property and equipment, net (including operating lease, right-of-use asset) 1,454  1,444  1,075  931  713 
Long-term Activity Ratio
Net fixed asset turnover (including operating lease, right-of-use asset)1 2.23 2.45 3.10 2.96 3.36
Benchmarks
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Competitors2
AbbVie Inc. 7.46 10.06 11.36 10.07 9.85
Amgen Inc. 4.58 4.11 4.54 4.37 4.41
Eli Lilly & Co. 2.63 2.66 2.75 2.59 2.57
Gilead Sciences Inc. 4.34 4.28 5.41 7.79 10.45
Johnson & Johnson 4.18 4.41 4.79 4.50 4.52
Merck & Co. Inc. 2.43 2.90 3.18 3.23 3.31
Moderna Inc. 0.52 0.00 0.00
Pfizer Inc. 2.74 3.39 4.01 3.79 3.97
Regeneron Pharmaceuticals Inc. 2.62 2.70 2.61 2.49 2.33
Thermo Fisher Scientific Inc. 4.82 4.69 5.85 5.17 7.09
Zoetis Inc. 2.79 2.94 3.51 3.70 3.54
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Sector
Pharmaceuticals, Biotechnology & Life Sciences 3.61 3.85 4.32 4.22 4.41
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Industry
Health Care 5.75 5.83 7.01 6.96 7.16

Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).

1 2020 Calculation
Net fixed asset turnover (including operating lease, right-of-use asset) = Revenue ÷ Property and equipment, net (including operating lease, right-of-use asset)
= 3,239 ÷ 1,454 = 2.23

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Net fixed asset turnover (including operating lease, right-of-use asset) An activity ratio calculated as total revenue divided by net fixed assets (including operating lease, right-of-use asset). Illumina Inc. net fixed asset turnover ratio (with operating lease, right-of-use asset) deteriorated from 2018 to 2019 and from 2019 to 2020.

Total Asset Turnover

Illumina Inc., total asset turnover calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2020 Dec 29, 2019 Dec 30, 2018 Dec 31, 2017 Dec 31, 2016
Selected Financial Data (US$ in millions)
Revenue 3,239  3,543  3,333  2,752  2,398 
Total assets 7,585  7,316  6,959  5,257  4,281 
Long-term Activity Ratio
Total asset turnover1 0.43 0.48 0.48 0.52 0.56
Benchmarks
Total Asset Turnover, Competitors2
AbbVie Inc. 0.30 0.37 0.55 0.40 0.39
Amgen Inc. 0.39 0.37 0.34 0.27 0.28
Eli Lilly & Co. 0.53 0.57 0.56 0.51 0.55
Gilead Sciences Inc. 0.36 0.36 0.34 0.37 0.53
Johnson & Johnson 0.47 0.52 0.53 0.49 0.51
Merck & Co. Inc. 0.52 0.55 0.51 0.46 0.42
Moderna Inc. 0.03 0.00 0.00
Pfizer Inc. 0.27 0.31 0.34 0.31 0.31
Regeneron Pharmaceuticals Inc. 0.50 0.53 0.57 0.67 0.70
Thermo Fisher Scientific Inc. 0.47 0.44 0.43 0.37 0.40
Zoetis Inc. 0.49 0.54 0.54 0.62 0.64
Total Asset Turnover, Sector
Pharmaceuticals, Biotechnology & Life Sciences 0.40 0.43 0.45 0.40 0.41
Total Asset Turnover, Industry
Health Care 0.64 0.65 0.67 0.66 0.68

Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).

1 2020 Calculation
Total asset turnover = Revenue ÷ Total assets
= 3,239 ÷ 7,585 = 0.43

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Total asset turnover An activity ratio calculated as total revenue divided by total assets. Illumina Inc. total asset turnover ratio improved from 2018 to 2019 but then deteriorated significantly from 2019 to 2020.

Equity Turnover

Illumina Inc., equity turnover calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2020 Dec 29, 2019 Dec 30, 2018 Dec 31, 2017 Dec 31, 2016
Selected Financial Data (US$ in millions)
Revenue 3,239  3,543  3,333  2,752  2,398 
Total Illumina stockholders’ equity 4,694  4,613  3,758  2,749  2,197 
Long-term Activity Ratio
Equity turnover1 0.69 0.77 0.89 1.00 1.09
Benchmarks
Equity Turnover, Competitors2
AbbVie Inc. 3.50 5.54 5.53
Amgen Inc. 2.58 2.30 1.80 0.86 0.73
Eli Lilly & Co. 4.35 8.56 2.50 1.97 1.52
Gilead Sciences Inc. 1.34 0.98 1.01 1.26 1.59
Johnson & Johnson 1.31 1.38 1.37 1.27 1.02
Merck & Co. Inc. 1.90 1.81 1.58 1.17 0.99
Moderna Inc. 0.08 0.00 0.00
Pfizer Inc. 0.66 0.82 0.85 0.74 0.89
Regeneron Pharmaceuticals Inc. 0.77 0.71 0.77 0.96 1.09
Thermo Fisher Scientific Inc. 0.93 0.86 0.88 0.82 0.85
Zoetis Inc. 1.77 2.31 2.67 3.00 3.29
Equity Turnover, Sector
Pharmaceuticals, Biotechnology & Life Sciences 1.36 1.46 1.40 1.15 1.10
Equity Turnover, Industry
Health Care 1.91 1.93 1.93 1.83 1.81

Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).

1 2020 Calculation
Equity turnover = Revenue ÷ Total Illumina stockholders’ equity
= 3,239 ÷ 4,694 = 0.69

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Equity turnover An activity ratio calculated as total revenue divided by shareholders’ equity. Illumina Inc. equity turnover ratio deteriorated from 2018 to 2019 and from 2019 to 2020.